Company Oxford Biomedica plc

Equities

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Oxford Biomedica plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - London S.E. Other stock markets 16:35:11 02/05/2024 BST			5-day change	1st Jan Change
300 ^GBX	+4.53%		+39.53%	+36.36%

04-29	FTSE 100 as investors look to Fed rate decision	AN
04-29	Transcript : Oxford Biomedica plc, Q4 2023 Earnings Call, Apr 29, 2024

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.

Number of employees: 714

GBP in Million	2022	Weight	2023	Weight	Delta
Platform 99.9 %	140	99.9 %	89	99.9 %	-36.09%
Product 0.1 %	0	0.1 %	0	0.1 %	+50.00%

GBP in Million	2022	Weight	2023	Weight	Delta
United States 73.4 %	62	44.0 %	66	73.4 %	+6.76%
Europe 22.1 %	28	20.0 %	20	22.1 %	-29.45%
United Kingdom 4.4 %	50	35.7 %	4	4.4 %	-92.02%

Managers	Title	Age	Since
Frank Mathias CEO	Chief Executive Officer	62	26/03/23
Stuart Paynter DFI	Director of Finance/CFO	52	28/08/17
Frederic Roch Doliveux CHM	Chairman	68	23/06/20
James Miskin CTO	Chief Tech/Sci/R&D Officer	-	31/12/99
Matthew Treagus CTO	Chief Tech/Sci/R&D Officer	-	31/07/21
Sophia Bolhassan IRC	Investor Relations Contact	-	30/09/21
Natalie Walter IRO	Public Communications Contact	50	30/04/19
Lisa James HRO	Human Resources Officer	-	31/12/15
Sebastien Ribault PRN	Corporate Officer/Principal	-	31/12/21
Kyriacos Mitrophanous PRN	Corporate Officer/Principal	-	31/12/96

Members of the board	Title	Age	Since
Leone Patterson BRD	Director/Board Member	61	30/04/23
Frederic Roch Doliveux CHM	Chairman	68	23/06/20
Stuart Henderson BRD	Director/Board Member	66	31/05/16
Heather Elizabeth Preston BRD	Director/Board Member	58	14/03/18
Michael Hayden BRD	Director/Board Member	72	14/07/21
Dame Davies BRD	Director/Board Member	73	28/02/21
Frank Mathias CEO	Chief Executive Officer	62	26/03/23
Catherine Moukheibir BRD	Director/Board Member	64	13/12/21
Stuart Paynter DFI	Director of Finance/CFO	52	28/08/17
Namrata Patel BRD	Director/Board Member	-	12/04/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	100,000,296	80,810,643 ( 80.81 %)	0	80.81 %

Name	Equities	%	Valuation
Novo Nordisk Fonden 11.80 %	11,798,802	11.80 %	30 M p
Vulpes Investment Management Pte Ltd. 8.442 %	8,437,978	8.442 %	21 M p
Liontrust Investment Partners LLP 8.048 %	8,044,568	8.048 %	20 M p
Compagnie Merieux Alliance SAS 6.152 %	6,149,374	6.152 %	16 M p
M&G Investment Management Ltd. 5.070 %	5,067,751	5.070 %	13 M p
Global Alpha Capital Management Ltd. 3.883 %	3,880,863	3.883 %	10 M p
Nine Ten Partners LP 3.389 %	3,387,228	3.389 %	9 M p
Serum Institute Life Sciences Pvt Ltd. 3.384 %	3,382,950	3.384 %	9 M p
Hargreaves Lansdown Asset Management Ltd. 3.032 %	3,031,200	3.032 %	8 M p
Vitruvian Partners LLP 3.006 %	3,004,567	3.006 %	8 M p

Oxford Biomedica Plc

Windrush Court Transport Way

OX4 6LT, Oxford

+44 1865 783 000

http://www.oxfordbiomedica.co.uk

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.87 GBP

Average target price

4.179 GBP

Spread / Average Target

+45.60%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
OXFORD BIOMEDICA PLC	+36.36%	358M
VERTEX PHARMACEUTICALS INCORPORATED	-0.92%	104B
REGENERON PHARMACEUTICALS, INC.	+6.41%	97.47B
ARGENX SE	+5.71%	22.25B
BIONTECH SE	-12.94%	21.68B
GENMAB A/S	-9.70%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-10.18%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+8.46%	14.39B
SAREPTA THERAPEUTICS, INC.	+38.33%	12.37B

Bio Therapeutic Drugs